Figure 4

BMS-204352 effects on glutamate and myo-inositol brain level. Mice (3-5 months) were administered with BMS-204352 at 2 mg/kg or vehicle (veh) and subjected to MRS test 30 min after the injection. Box plots (shown as the minimum, 1st quartile, mean, median, 2nd quartile and maximum values) represent (a) glutamate and (b) myo-inositol concentrations in arbitrary unit (AU), after normalization by Creatine/Phosphocreatine, in vehicle or BMS-204352-treated-WT and Fmr1 KO mice. Glutamate level was significantly decreased in Fmr1 KO mice compared to WT, whereas myo-inositol concentration was increased. Furthermore, a single injection of BMS-204352 rescued a WT like metabolites concentration. Significance between WT and KO was determined using Mann-Whitney test and impact of treatment was determined by Wilcoxon test. NS, not significant; **p < 0.01 for genotype comparison; ^#p < 0.05 for treatment comparison (n: WT-veh = 10; WT-2 mg/kg = 10; KO-veh = 10; KO-2 mg/kg = 10).